AR071574A1 - Uso de variantes de igf -i pegiladas para el tratamiento de trastornos neuromusculares - Google Patents
Uso de variantes de igf -i pegiladas para el tratamiento de trastornos neuromuscularesInfo
- Publication number
- AR071574A1 AR071574A1 ARP090101168A ARP090101168A AR071574A1 AR 071574 A1 AR071574 A1 AR 071574A1 AR P090101168 A ARP090101168 A AR P090101168A AR P090101168 A ARP090101168 A AR P090101168A AR 071574 A1 AR071574 A1 AR 071574A1
- Authority
- AR
- Argentina
- Prior art keywords
- igf
- seq
- pegylated
- variant
- amino acid
- Prior art date
Links
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title abstract 9
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 9
- 208000018360 neuromuscular disease Diseases 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 229920001223 polyethylene glycol Polymers 0.000 abstract 5
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- 102220638483 Protein PML_K65R_mutation Human genes 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 230000004075 alteration Effects 0.000 abstract 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 3
- 102220350531 c.80A>G Human genes 0.000 abstract 3
- 125000003827 glycol group Chemical group 0.000 abstract 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 2
- 102220638482 Protein PML_K68R_mutation Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000044162 human IGF1 Human genes 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000015404 Amino Acid Receptors Human genes 0.000 abstract 1
- 108010025177 Amino Acid Receptors Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004181 riluzole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere el uso farmacéutico de variantes del IGF-I modificado con polietilenglicol (= PEGilado) para el tratamiento, prevencion y/o demora de la progresion de trastornos neuromusculares, en particular de la esclerosis lateral amiotrofica (ELA). Más específicamente, la presente se refiere al uso de una variante de IGF-I PEGilada para la fabricacion de una composicion farmacéutica destinada al tratamiento, prevencion y/o demora de trastornos neuromusculares, en particular de la ELA, dicha variante de IGF-I PEGilada se caracteriza porque se deriva de la secuencia de aminoácidos del IGF-I humano de tipo salvaje (SEQ ID N°:1) y lleva una o dos alteraciones de aminoácido en las posiciones 27, 65 y 68, de modo que uno o dos de los aminoácidos de las posiciones 27, 65 y 68 sea o sean aminoácidos polares, pero no la lisina, y el PEG está unido por lo menos a un resto lisina. Reivindicacion 2: Uso reivindicado en la reivindicacion 1, en el que dicha variante de IGF-I PEGilada se caracteriza por las siguientes alteraciones de aminoácidos de la secuencia de aminoácidos del IGF-I humano de tipo salvaje (SEQ ID N°:1); (a) K65R y K68R (SEQ ID N°:2); (b) K27R y K68R (SEQ ID N°:3), o (c) K27R y K65R (SEQ ID N°:4). Reivindicacion 3: Uso reivindicado en la reivindicacion 1 o 2, en el que dicha variante de IGF-I PEGilada es mono-PEGilada en K68 y se caracteriza por las siguientes alteraciones de la secuencia de aminoácidos del IGF-I humano de tipo salvaje (SEQ ID N°:1); K27R y K65R (SEQ ID N°:4). Reivindicacion 4: Uso reivindicado en una cualquiera de las reivindicaciones de 1 a 3, en el que dicho PEG tiene un peso molecular total de 20 a 100 kDa. Reivindicacion 7: Uso reivindicado en una cualquiera de las reivindicaciones de 1 a 6, en el que dicha variante de IGF-l PEGilada está caracterizada porque hasta tres aminoácidos del extremo N están truncados. Reivindicacion 8: Uso reivindicado en una cualquiera de las reivindicaciones de 1 a 7, en el que dicha variante de IGF-I PEGilada se caracteriza porque el o los grupos polietilenglicol es o son grupos polietilenglicol ramificados. Reivindicacion 12: Uso reivindicado en la reivindicacion 11, en el que el segundo compuesto farmacologicamente activo de la combinacion es por lo menos un neuroprotector que tiene efecto inhibidor de la liberacion de glutamato o efecto de inactivacion de los canales de sodio dependientes de voltaje o la capacidad de interferir en los episodios intracelulares que siguen a la union del transmisor con los receptores de aminoácidos excitantes. Reivindicacion 13: Uso reivindicado en la reivindicacion 12, en el que el segundo compuesto farmacologicamente activo es riluzol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08153994 | 2008-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071574A1 true AR071574A1 (es) | 2010-06-30 |
Family
ID=41021043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101168A AR071574A1 (es) | 2008-04-03 | 2009-04-01 | Uso de variantes de igf -i pegiladas para el tratamiento de trastornos neuromusculares |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20090253628A1 (es) |
| EP (1) | EP2274016B1 (es) |
| JP (1) | JP5173018B2 (es) |
| KR (1) | KR101273187B1 (es) |
| CN (1) | CN101983074A (es) |
| AR (1) | AR071574A1 (es) |
| AU (1) | AU2009231394B2 (es) |
| BR (1) | BRPI0910338A2 (es) |
| CA (1) | CA2720408C (es) |
| CL (1) | CL2009000803A1 (es) |
| CR (1) | CR11692A (es) |
| EC (1) | ECSP10010516A (es) |
| ES (1) | ES2388827T3 (es) |
| IL (1) | IL208106A (es) |
| MX (1) | MX2010010495A (es) |
| PE (1) | PE20091715A1 (es) |
| RU (1) | RU2010144014A (es) |
| TW (1) | TW200944237A (es) |
| WO (1) | WO2009121759A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| BRPI0715754A2 (pt) | 2006-08-31 | 2013-07-09 | Hoffmann La Roche | mÉtodo para a produÇço de fator do crescimento similar Á insulina i |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| MX2010010313A (es) * | 2008-04-03 | 2010-11-05 | Hoffmann La Roche | Analisis de factor de crecimiento pegilado similar a insulina. |
| US20110152188A1 (en) | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| US20140357558A1 (en) * | 2011-06-24 | 2014-12-04 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of spinal muscular atrophy |
| CN104853778A (zh) * | 2012-10-24 | 2015-08-19 | 第一三共株式会社 | 用于肌萎缩性侧索硬化的治疗剂 |
| EP3052123A1 (en) | 2013-10-02 | 2016-08-10 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
| IL270971B1 (en) | 2017-05-30 | 2024-02-01 | Teijin Pharma Ltd | Antibody against the 1-IGF receptor |
| CN111094327A (zh) * | 2017-08-16 | 2020-05-01 | Lgv1有限公司 | Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型 |
| JP7246409B2 (ja) | 2018-12-03 | 2023-03-27 | 帝人ファーマ株式会社 | 抗ｉｇｆ－ｉ受容体ヒト化抗体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US5135956A (en) * | 1988-10-18 | 1992-08-04 | The Regents Of The University Of California | Method of using cytoprotective alcohols to treat neural disease and neural injury |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5158875A (en) * | 1989-08-25 | 1992-10-27 | Amgen Inc. | Production of biologically active insulin-like growth factor i from high expression host cell systems |
| NZ236819A (en) * | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
| US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| DK0597033T3 (da) * | 1991-08-01 | 1997-06-02 | Genentech Inc | IGF-1 til forbedring af den neurale tilstand |
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| US5395822A (en) * | 1993-09-20 | 1995-03-07 | Izumi; Yukitoshi | Use of pyruvate to prevent neuronal degeneration associated with ischemia |
| AU2601895A (en) * | 1994-05-24 | 1995-12-18 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5906976A (en) * | 1996-10-22 | 1999-05-25 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Method and composition for treating neuronal degeneration |
| DK1141014T3 (da) * | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulinlignende vækstfaktor (IGF) i mutantvariant |
| WO2000040612A1 (en) * | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| AR059088A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una proteina para esclerosis lateral amiotrofica |
| CL2007002502A1 (es) * | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| BRPI0715754A2 (pt) * | 2006-08-31 | 2013-07-09 | Hoffmann La Roche | mÉtodo para a produÇço de fator do crescimento similar Á insulina i |
-
2009
- 2009-03-24 EP EP09727511A patent/EP2274016B1/en active Active
- 2009-03-24 CN CN2009801121265A patent/CN101983074A/zh active Pending
- 2009-03-24 MX MX2010010495A patent/MX2010010495A/es active IP Right Grant
- 2009-03-24 ES ES09727511T patent/ES2388827T3/es active Active
- 2009-03-24 RU RU2010144014/10A patent/RU2010144014A/ru unknown
- 2009-03-24 JP JP2011502341A patent/JP5173018B2/ja not_active Expired - Fee Related
- 2009-03-24 WO PCT/EP2009/053465 patent/WO2009121759A2/en active Application Filing
- 2009-03-24 KR KR1020107021584A patent/KR101273187B1/ko not_active IP Right Cessation
- 2009-03-24 BR BRPI0910338-4A patent/BRPI0910338A2/pt not_active IP Right Cessation
- 2009-03-24 AU AU2009231394A patent/AU2009231394B2/en not_active Ceased
- 2009-03-24 CA CA2720408A patent/CA2720408C/en not_active Expired - Fee Related
- 2009-03-26 US US12/411,673 patent/US20090253628A1/en not_active Abandoned
- 2009-04-01 AR ARP090101168A patent/AR071574A1/es unknown
- 2009-04-01 PE PE2009000477A patent/PE20091715A1/es not_active Application Discontinuation
- 2009-04-01 TW TW098110905A patent/TW200944237A/zh unknown
- 2009-04-02 CL CL2009000803A patent/CL2009000803A1/es unknown
-
2010
- 2010-09-13 IL IL208106A patent/IL208106A/en not_active IP Right Cessation
- 2010-09-27 CR CR11692A patent/CR11692A/es not_active Application Discontinuation
- 2010-10-01 EC EC2010010516A patent/ECSP10010516A/es unknown
-
2011
- 2011-04-01 US US13/078,106 patent/US20110183903A1/en not_active Abandoned
-
2013
- 2013-01-17 US US13/743,406 patent/US20140073567A1/en not_active Abandoned
-
2015
- 2015-04-13 US US14/684,772 patent/US20150273023A1/en not_active Abandoned
-
2016
- 2016-07-26 US US15/220,380 patent/US20170014488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009121759A2 (en) | 2009-10-08 |
| WO2009121759A3 (en) | 2010-03-25 |
| JP2011518778A (ja) | 2011-06-30 |
| IL208106A0 (en) | 2010-12-30 |
| CA2720408C (en) | 2016-09-06 |
| US20110183903A1 (en) | 2011-07-28 |
| EP2274016B1 (en) | 2012-07-25 |
| JP5173018B2 (ja) | 2013-03-27 |
| TW200944237A (en) | 2009-11-01 |
| AU2009231394B2 (en) | 2013-09-05 |
| CL2009000803A1 (es) | 2010-05-07 |
| CR11692A (es) | 2010-12-09 |
| MX2010010495A (es) | 2010-10-15 |
| ECSP10010516A (es) | 2010-11-30 |
| US20170014488A1 (en) | 2017-01-19 |
| KR20100119816A (ko) | 2010-11-10 |
| CN101983074A (zh) | 2011-03-02 |
| EP2274016A2 (en) | 2011-01-19 |
| US20150273023A1 (en) | 2015-10-01 |
| KR101273187B1 (ko) | 2013-06-17 |
| US20140073567A1 (en) | 2014-03-13 |
| RU2010144014A (ru) | 2012-05-27 |
| BRPI0910338A2 (pt) | 2020-08-18 |
| AU2009231394A1 (en) | 2009-10-08 |
| CA2720408A1 (en) | 2009-10-08 |
| IL208106A (en) | 2015-09-24 |
| US20090253628A1 (en) | 2009-10-08 |
| ES2388827T3 (es) | 2012-10-19 |
| PE20091715A1 (es) | 2009-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071574A1 (es) | Uso de variantes de igf -i pegiladas para el tratamiento de trastornos neuromusculares | |
| EA201790871A1 (ru) | Нацеленные конъюгатные композиции xten и способы их получения | |
| EP3406347A3 (en) | Xten conjugate compositions and methods of making same | |
| AR088161A1 (es) | Analogos de glucagon | |
| MX2009003246A (es) | Análogos de ghrelina sustituidos en el terminal n. | |
| WO2011159895A3 (en) | Single chain insulin agonists exhibiting high activity at the insulin receptor | |
| CO6650414A2 (es) | Grupos objetivos de receptro de complemento 2 mejorados | |
| CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| CO6331292A2 (es) | Compuestos de insulina lispro pegilada | |
| MX2019000661A (es) | Nuevos analogos de urocortina-2 modificados con acido graso para el tratamiento de diabetes y enfermedad renal cronica. | |
| PE20141219A1 (es) | Profarmaco de adrenomedulina basado en polietilenglicol y su uso | |
| ECSP099622A (es) | Coagonistas de receptor de glucagón/glp-1 | |
| PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
| CY1113299T1 (el) | Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| TR201906255T4 (tr) | Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar. | |
| MX359680B (es) | Vacunas peptídicas para cánceres que expresan antígenos hig2 asociados con tumores. | |
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| BR112013011282A2 (pt) | formulações baseadas em ácido hialurônico | |
| AU2011336397A8 (en) | Chemokine CXCR4 receptor modulators and uses related thereto | |
| WO2012002668A3 (en) | Novel peptide and use thereof | |
| WO2015183995A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| JP2013509432A5 (es) | ||
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |